$38.64
Insights on Inari Medical Inc
Revenue is up for the last 15 quarters, 25.39M → 132.09M (in $), with an average increase of 10.7% per quarter
Netprofit is down for the last 2 quarters, 3.16M → -4.66M (in $), with an average decrease of 247.6% per quarter
In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 71.2%
In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 129.3%
1.81%
Downside
Day's Volatility :3.19%
Upside
1.4%
0.75%
Downside
52 Weeks Volatility :46.62%
Upside
46.22%
Period | Inari Medical Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -33.3% | -0.7% | 0.0% |
6 Months | -31.87% | 6.6% | 0.0% |
1 Year | -39.47% | 3.7% | -1.5% |
3 Years | -62.48% | 14.0% | -21.8% |
Market Capitalization | 2.3B |
Book Value | $8.05 |
Earnings Per Share (EPS) | -0.03 |
Wall Street Target Price | 73.18 |
Profit Margin | -0.33% |
Operating Margin TTM | 0.84% |
Return On Assets TTM | -0.39% |
Return On Equity TTM | -0.37% |
Revenue TTM | 493.6M |
Revenue Per Share TTM | 8.7 |
Quarterly Revenue Growth YOY | 22.6% |
Gross Profit TTM | 339.0M |
EBITDA | 2.0M |
Diluted Eps TTM | -0.03 |
Quarterly Earnings Growth YOY | -0.84 |
EPS Estimate Current Year | -0.55 |
EPS Estimate Next Year | 0.2 |
EPS Estimate Current Quarter | 0.01 |
EPS Estimate Next Quarter | -0.06 |
What analysts predicted
Upside of 89.39%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 6.8M | - |
Net Income | -10.2M | - |
Net Profit Margin | -148.67% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 51.1M | ↑ 648.7% |
Net Income | -1.9M | ↓ 81.22% |
Net Profit Margin | -3.73% | ↑ 144.94% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 139.7M | ↑ 173.17% |
Net Income | 13.8M | ↓ 823.03% |
Net Profit Margin | 9.87% | ↑ 13.6% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 277.0M | ↑ 98.31% |
Net Income | 9.8M | ↓ 28.64% |
Net Profit Margin | 3.55% | ↓ 6.32% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 383.5M | ↑ 38.45% |
Net Income | -29.3M | ↓ 397.43% |
Net Profit Margin | -7.63% | ↓ 11.18% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 493.6M | ↑ 28.73% |
Net Income | -1.6M | ↓ 94.41% |
Net Profit Margin | -0.33% | ↑ 7.3% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 96.2M | ↑ 3.73% |
Net Income | -10.2M | ↓ 0.33% |
Net Profit Margin | -10.55% | ↑ 0.43% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 107.8M | ↑ 12.02% |
Net Income | -5.8M | ↓ 42.89% |
Net Profit Margin | -5.38% | ↑ 5.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 116.2M | ↑ 7.79% |
Net Income | -2.2M | ↓ 61.75% |
Net Profit Margin | -1.91% | ↑ 3.47% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 119.0M | ↑ 2.44% |
Net Income | 2.1M | ↓ 194.0% |
Net Profit Margin | 1.75% | ↑ 3.66% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 126.4M | ↑ 6.19% |
Net Income | 3.2M | ↑ 51.65% |
Net Profit Margin | 2.5% | ↑ 0.75% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 132.1M | ↑ 4.53% |
Net Income | -4.7M | ↓ 247.6% |
Net Profit Margin | -3.53% | ↓ 6.03% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 26.9M | - |
Total Liabilities | 66.3M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 44.5M | ↑ 65.59% |
Total Liabilities | 83.7M | ↑ 26.14% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 214.1M | ↑ 380.6% |
Total Liabilities | 13.8M | ↓ 83.47% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 311.5M | ↑ 45.52% |
Total Liabilities | 72.3M | ↑ 422.71% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 504.2M | ↑ 61.82% |
Total Liabilities | 87.2M | ↑ 20.48% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 674.2M | ↑ 33.74% |
Total Liabilities | 209.3M | ↑ 140.19% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 487.8M | ↑ 0.73% |
Total Liabilities | 72.7M | ↑ 3.17% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 504.2M | ↑ 3.35% |
Total Liabilities | 87.2M | ↑ 19.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 506.5M | ↑ 0.47% |
Total Liabilities | 79.8M | ↓ 8.44% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 525.0M | ↑ 3.64% |
Total Liabilities | 89.3M | ↑ 11.94% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 548.8M | ↑ 4.55% |
Total Liabilities | 96.7M | ↑ 8.25% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 674.2M | ↑ 22.85% |
Total Liabilities | 209.3M | ↑ 116.48% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.9M | - |
Investing Cash Flow | -753.0K | - |
Financing Cash Flow | 26.8M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.9M | ↓ 54.68% |
Investing Cash Flow | -3.1M | ↑ 317.53% |
Financing Cash Flow | 10.2M | ↓ 61.79% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.9M | ↓ 138.74% |
Investing Cash Flow | -55.4M | ↑ 1663.26% |
Financing Cash Flow | 144.1M | ↑ 1309.64% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 25.5M | ↑ 1232.95% |
Investing Cash Flow | -51.0M | ↓ 7.96% |
Financing Cash Flow | 4.1M | ↓ 97.17% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.0M | ↓ 154.82% |
Investing Cash Flow | -195.2M | ↑ 282.61% |
Financing Cash Flow | 177.1M | ↑ 4249.08% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.1M | ↑ 326.85% |
Investing Cash Flow | 13.4M | ↓ 113.16% |
Financing Cash Flow | 3.9M | ↓ 343.26% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 11.3M | ↓ 186.14% |
Investing Cash Flow | -33.2M | ↓ 348.07% |
Financing Cash Flow | -1.7M | ↓ 143.53% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.0M | ↓ 117.89% |
Investing Cash Flow | -4.0M | ↓ 87.84% |
Financing Cash Flow | 2.5M | ↓ 246.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 9.8M | ↓ 584.85% |
Investing Cash Flow | -6.1M | ↑ 50.38% |
Financing Cash Flow | -2.4M | ↓ 195.38% |
Sell
Neutral
Buy
Inari Medical Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Inari Medical Inc | -7.04% | -31.87% | -39.47% | -62.48% | -8.96% |
Stryker Corporation | -5.1% | 24.37% | 15.51% | 30.88% | 86.41% |
Boston Scientific Corp. | 1.07% | 34.02% | 31.68% | 66.24% | 93.56% |
Edwards Lifesciences Corp. | -6.04% | 25.15% | 3.43% | -1.49% | 47.65% |
Abbott Laboratories | -5.82% | 10.82% | 1.68% | -14.96% | 43.26% |
Medtronic Plc | -5.47% | 8.78% | -3.15% | -37.3% | -6.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Inari Medical Inc | NA | NA | NA | -0.55 | 0.0 | 0.0 | NA | 8.05 |
Stryker Corporation | 40.98 | 40.98 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 63.66 | 63.66 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 39.15 | 39.15 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 11.06 |
Abbott Laboratories | 33.4 | 33.4 | 5.99 | 4.59 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.16 | 25.16 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Inari Medical Inc | Buy | $2.3B | -8.96% | NA | -0.33% |
Stryker Corporation | Buy | $128.5B | 86.41% | 40.98 | 15.44% |
Boston Scientific Corp. | Buy | $100.1B | 93.56% | 63.66 | 11.18% |
Edwards Lifesciences Corp. | Buy | $54.2B | 47.65% | 39.15 | 23.36% |
Abbott Laboratories | Buy | $189.5B | 43.26% | 33.4 | 14.27% |
Medtronic Plc | Buy | $105.2B | -6.1% | 25.16 | 13.0% |
BlackRock Inc
Vanguard Group Inc
Wellington Management Company LLP
Franklin Resources Inc
AllianceBernstein L.P.
State Street Corporation
Inari Medical Inc’s price-to-earnings ratio stands at None
Read Moreinari medical is a medical device company pioneering devices for the interventional treatment of vascular thrombi and emboli.
Organization | Inari Medical Inc |
Employees | 1300 |
CEO | Mr. Andrew J. Hykes |
Industry | Health Technology |
Vanguard Ultra Short Bond Et
$38.64
-0.16%
Surgery Partners Inc
$38.64
-0.16%
Sl Green Realty Corp.
$38.64
-0.16%
Goldman Sachs Activebeta Int
$38.64
-0.16%
Allegro Microsystems, Inc.
$38.64
-0.16%
Cleanspark Inc
$38.64
-0.16%
Chart Industries Inc.
$38.64
-0.16%
Agree Realty Corp
$38.64
-0.16%
Joby Aviation Inc
$38.64
-0.16%